A Randomized Phase Ii Trial of Ridaforolimus, Dalotuzumab, and Exemestane Compared with Ridaforolimus and Exemestane in Patients with Advanced Breast Cancer
AuthID
P-00N-1B3
P-00N-1B3
© 2024 CRACS & Inesc TEC - All Rights Reserved Política de Privacidade | Terms of Service